Viatris Announced That The Antitrust Division Of U.S. Department Of Justice Has Advised That It No Longer Considers Mylan, And Its Former President, Rajiv Malik, A Subject Of Its Antitrust Investigation In The Generic Drug Industry
Portfolio Pulse from Benzinga Newsdesk
Viatris announced that the U.S. Department of Justice's Antitrust Division no longer considers Mylan and its former president, Rajiv Malik, subjects of its antitrust investigation in the generic drug industry. The DOJ's Civil Division also does not expect to take further actions regarding a civil investigative demand related to generic drug pricing and sales.
July 02, 2024 | 11:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The DOJ has dropped its antitrust and civil investigations into Mylan and its former president, Rajiv Malik, which is positive news for Viatris.
The end of DOJ investigations removes legal uncertainties and potential liabilities, which is likely to have a positive impact on Viatris' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100